Pfizer (PFE)

Pfizer (NYSE:PFE) Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining COVID-19-related demand and upcoming losses of exclusivity for certain products. Speaking at a Mo

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the dividend.

Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance. Ryan Crowe, senior vice president of investor relations and strategic ana

Rock-bottom prices don’t always mean rock-bottom businesses. The stocks we’re examining today have all touched their 52-week lows, creating a classic investo...

Novavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi’s commercial rollout of NUVAXOVID, combination vaccine development and early

The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors.

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime soon?

Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.

The company is coming back into the spotlight thanks to recent developments.

Patient investors who buy the stock may be rewarded over the long term.

If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.

Salesforce powers the engine behind America’s most ambitious brands. From retail giants to global banks, its footprint is massive. Therefore, marketers eve

As investors hedge against AI-trade valuation worries, dividend payers gain favor. AT&T, ONEOK, and Pfizer offer yields from 4.3% to 6.1% with distinct capital-return strategies.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...